title: Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).
abstract: The post-exposure therapeutic efficacy of injectable peramivir against highly pathogenic avian influenza type A H5N1 was evaluated in mice and in ferrets. Seventy to eighty percent of the H5N1-infected peramivir-treated mice, and 70% in the oseltamivir treated mice survived the 15-day study period, as compared to 36% in control (vehicle) group. Ferrets were infected intranasally with H5N1 followed by treatment with multiple doses of peramivir. In two of three trials, a statistically significant increase in survival over a 16-18 day period resulted from peramivir treatment, with improved survival of 40-64% in comparison to mock-treated or untreated animals. Injected peramivir mitigates virus-induced disease, reduces infectious virus titers in the lungs and brains and promotes survival in ferrets infected intranasally with this highly neurovirulent isolate. A single intramuscular peramivir injection protected mice against severe disease outcomes following infection with highly pathogenic avian influenza and multi-dose treatment was efficacious in ferrets.
authors.affiliation: Center for Biodefense and Emerging Infectious Diseases, Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
authors.forename: Nadezhda E
authors.initials: NE
authors.lastname: Yun
authors.forename: Nathaniel S
authors.initials: NS
authors.lastname: Linde
authors.forename: Michele A
authors.initials: MA
authors.lastname: Zacks
authors.forename: Ian G
authors.initials: IG
authors.lastname: Barr
authors.forename: Aeron C
authors.initials: AC
authors.lastname: Hurt
authors.forename: Jeanon N
authors.initials: JN
authors.lastname: Smith
authors.forename: Natallia
authors.initials: N
authors.lastname: Dziuba
authors.forename: Michael R
authors.initials: MR
authors.lastname: Holbrook
authors.forename: Lifang
authors.initials: L
authors.lastname: Zhang
authors.forename: John M
authors.initials: JM
authors.lastname: Kilpatrick
authors.forename: C Shane
authors.initials: CS
authors.lastname: Arnold
authors.forename: Slobodan
authors.initials: S
authors.lastname: Paessler
mesh_terms: D000146:Acids, Carbocyclic; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D003517:Cyclopentanes / Q000008:administration & dosage / Q000627:therapeutic use*; D005289:Ferrets; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D053124:Influenza A Virus, H5N1 Subtype / Q000187:drug effects*; D007273:Injections, Intramuscular; D008168:Lung / Q000821:virology; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000821:virology; D053139:Oseltamivir / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D053139:Oseltamivir; C414210:peramivir